Products Categories
| CAS No.: | 3286-46-2 |
|---|---|
| Name: | Bisibutiamine |
| Article Data: | 8 |
| Molecular Structure: | |
|
|
|
| Formula: | C32H46N8O6S2 |
| Molecular Weight: | 702.899 |
| Synonyms: | Arcalion;Bisibutiamine;[4-[(4-Amino-2-methylpyrimidin-5-yl)methylformylamino]-3-[2-[(4-amino-2-methylpyrimidin-5-yl)methylformylamino]-5-(2-methylpropanoyloxy)pent-2-en-3-yl]disulfanylpent-3-enyl] 2-methylpropanoate; |
| EINECS: | 221-937-3 |
| Density: | 1.268 g/cm3 |
| Melting Point: | 140.5-141.5 °C |
| Boiling Point: | 892.5 °C at 760 mmHg |
| Flash Point: | 493.5 °C |
| Appearance: | White to off-white crystalline powder |
| PSA: | 247.42000 |
| LogP: | 7.12200 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 4075-81-4Propanoicacid, calcium salt (2:1)
- 25812-30-0Gemfibrozil
- 81403-68-1Alfuzosin hydrochloride
- 126784-99-419-Norpregna-4,9-diene-3,20-dione,17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11b)-
- 551-93-92'-Aminoacetophenone
- 7758-99-8Sulfuric acidcopper(2+) salt (1:1), hydrate (1:5)
- 151533-22-1Calcium levomefolate
- 106-51-41,4-Benzoquinone
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
History
The history of sulbutiamine is closely tied to the study of thiamine in Japan. A deficiency of thiamine causes a nervous system disorder called beriberi. Until the twentieth century, beriberi was prevalent in Japan and other Asian countries due to the widespread dependence on white rice as a staple food. The relationship between beriberi and diet was first noted by a navy surgeon named Takaki Kanehiro.Additional work resulted in the discovery of thiamine, which was isolated in 1926 and synthesized in 1936. The establishment of a Vitamin B Research Committee in Japan led to additional scientific investigation into the properties of thiamine and its derivatives.
The first lipophilic thiamine derivative to be discovered was allithiamine, which was isolated from garlic (Allium sativum) in 1951. Allithiamine is an allyl disulfide derivative. After the discovery of allithiamine, several additional derivatives were synthesized with the hope that they would have better pharmacokinetic properties than thiamine. Thiamine is unable to diffuse across plasma membranes because it has a positively charged thiazole moiety. Instead, it must be transported across plasma membranes by high affinity carriers, and the rate of transport is low. Sulbutiamine overcomes the poor oral bioavailability of thiamine because it is highly lipophilic. It is not clear when sulbutiamine was first synthesized, but the earliest reference to it in the literature is from 1973.
Specification
The Sulbutiamine, with the CAS registry number 3286-46-2, is also known as O-Isobutyroylthiamine disulfide. It belongs to the product category of Vitamins and derivatives.Its IUPAC name is called [(E)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(E)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-(2-methylpropanoyloxy)pent-2-en-3-yl]disulfanyl]pent-3-enyl]2-methylpropanoate. This chemical's classification code is Drug / Therapeutic Agent. Sulbutiamine (brand name: Arcalion) is a synthetic derivative of thiamine. It is the only compound used to treat asthenia that is known to selectively target the areas that are involved in the condition.
Physical properties of Sulbutiamine are: (1)ACD/LogP: 6.154; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): 5.39; (4)ACD/LogD (pH 7.4): 6.14; (5)ACD/BCF (pH 5.5): 4849.95; (6)ACD/BCF (pH 7.4): 26983.07; (7)ACD/KOC (pH 5.5): 9191.60; (8)ACD/KOC (pH 7.4): 51138.15; (9)#H bond acceptors: 14; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 19; (12)Index of Refraction: 1.602; (13)Molar Refractivity: 190.198 cm3; (14)Molar Volume: 554.327 cm3; (15)Polarizability: 75.4 10-24cm3; (16)Surface Tension: 57.898998260498 dyne/cm; (17)Density: 1.268 g/cm3; (18)Flash Point: 493.539 °C; (19)Enthalpy of Vaporization: 129.752 kJ/mol; (20)Boiling Point: 892.455 °C at 760 mmHg
You can still convert the following datas into molecular structure:
(1)InChI=1S/C32H46N8O6S2/c1-19(2)31(43)45-11-9-27(21(5)39(17-41)15-25-13-35-23(7)37-29(25)33)47-48-28(10-12-46-32(44)20(3)4)22(6)40(18-42)16-26-14-36-24(8)38-30(26)34/h13-14,17-20H,9-12,15-16H2,1-8H3,(H2,33,35,37)(H2,34,36,38)/b27-21+,28-22+;
(2)InChIKey=CKHJPWQVLKHBIH-GPAWKIAZSA-N;
(3)SmilesCc1ncc(CN(C=O)C(\C)=C(/SSC(\CCOC(C(C)C)=O)=C(\C)N(C=O)Cc2cnc(C)nc2N)CCOC(C(C)C)=O)c(N)n1;
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | > 2500mg/kg (2500mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| mouse | LD50 | oral | > 5gm/kg (5000mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| mouse | LD50 | subcutaneous | > 3gm/kg (3000mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| rat | LD50 | intraperitoneal | 660mg/kg (660mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| rat | LD50 | intravenous | 110mg/kg (110mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| rat | LD50 | oral | > 5gm/kg (5000mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. | |
| rat | LD50 | subcutaneous | 850mg/kg (850mg/kg) | Drugs in Japan Vol. 6, Pg. 606, 1982. |